Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best multibagger penny stocks to invest in. On March 31, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) and Citeline expanded their strategic partnership to further develop the artificial intelligence-based ClinTech platform.
Photo by Pietro Jeng on Pexels
The expanded partnership also underscores the company’s commitment to building a more predictive and patient-centric biopharmaceutical ecosystem. It also follows the integration of Citeline’s SmartSolutions into the Recursion platform to provide data access during the early stages of development.
The expanded partnership paves the way to integrate Citeline’s real-world data and evidence capabilities into Recursion’s end-to-end platform. The integration will strengthen the foundation of the platform, enabling more accurate test design, better site selection, and informed development decisions.
The addition of Citeline’s data and evidence capabilities to the company’s robust platform is also set to support the development of the project. The ClinTech platform is already delivering results, including 30% to 60% improvements in enrollment, affirming the importance of integration.
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is a clinical-stage “TechBio” company that uses artificial intelligence (AI), machine learning, automation and high-throughput biology to improve drug discovery and development.
While we recognize the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: The Motley Fool’s 10 High Growth Stock Picks and the 8 best blue-chip AI stocks to buy now.
Disclosure: None. Follow Insider Monkey on Google News.